NCT02629419View on ClinicalTrials.gov

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 27, 2016

Primary Completion Date

November 9, 2021

Study Completion Date

August 6, 2022

Conditions
Candidiasis, Chronic Mucocutaneous
Interventions
DRUG

Amphotericin B

Oral lipid nanocrystal formulation of amphotericin B

Trial Locations (1)

20892

National Institute of Allergy and Infectious Disease (NIAID), Bethesda

All Listed Sponsors
lead

Matinas BioPharma Nanotechnologies, Inc.

INDUSTRY

NCT02629419 - CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis | Biotech Hunter | Biotech Hunter